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Abstract
Background: Xenobiotics represent an environmental stress and as such are a source for antibiotics, including the
isoquinoline (IQ) compound IQ-143. Here, we demonstrate the utility of complementary analysis of both host and
pathogen datasets in assessing bacterial adaptation to IQ-143, a synthetic analog of the novel type N,C-coupled
naphthyl-isoquinoline alkaloid ancisheynine.
Results: Metabolite measurements, gene expression data and functional assays were combined with metabolic
modeling to assess the effects of IQ-143 on Staphylococcus aureus, Staphylococcus epidermidis and human cell lines,
as a potential paradigm for novel antibiotics. Genome annotation and PCR validation identified novel enzymes in
the primary metabolism of staphylococci. Gene expression response analysis and metabolic modeling
demonstrated the adaptation of enzymes to IQ-143, including those not affected by significant gene expression
changes. At lower concentrations, IQ-143 was bacteriostatic, and at higher concentrations bactericidal, while the
analysis suggested that the mode of action was a direct interference in nucleotide and energy metabolism.
Experiments in human cell lines supported the conclusions from pathway modeling and found that IQ-143 had
low cytotoxicity.
Conclusions: The data suggest that IQ-143 is a promising lead compound for antibiotic therapy against
staphylococci. The combination of gene expression and metabolite analyses with in silico modeling of metabolite
pathways allowed us to study metabolic adaptations in detail and can be used for the evaluation of metabolic
effects of other xenobiotics.
Background
Antibiotic treatment of infectious diseases has become
increasingly challenging as pathogenic bacteria have
acquired a broad spectrum of resistance mechanisms. In
particular, the emergence and spread of multi-resistant
staphylococci has progressed to a global health threat
[1]. They are not only resistant to almost all treatments,
but also adapt very well to different conditions in the
host, including persistence [2-4]. In the face of
increasing resistance against antibiotics as well as persis-
tence of staphylococci in the patient, an intensive search
of new antibacterial lead compounds addressing new
targets is urgently required.
Currently, several ‘-omics’ techniques are available, but
they are expensive and, in general, only limited informa-
tion is available for each type of data [5]. We will show
how different data sets for studying the metabolic effects
of a xenobiotic can be efficiently combined to derive a
maximum of information utilizing pathway modeling
[6-8] while validating the latter by experimental data.
A new emerging paradigm for investigating drug
effects and toxicity is followed here: instead of consider-
ing the body of the studied organism as a black box and
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just identifying toxic or antibiotic concentrations, geno-
mics and post-genomics strategies are used to reveal
affected pathways. This combination enables a more
rapid understanding of metabolic effects and at the
same time also reveals side effects in unprecedented
detail, leading to a network paradigm: a substance is not
just toxic or nontoxic but has, in general, stronger or
weaker and concentration-dependent network effects.
In our studies we observed a drastic change in meta-
bolic activity after administration of the isoquinolinium
salt IQ-143 (Figure 1) and show for staphylococci that
this compound is a xenobiotic with antibiotic properties.
IQ-143 constitutes a structurally simplified analogue of
a new subclass of bioactive natural products, the N,C-
coupled naphthylisoquinoline alkaloids, which were first
isolated from tropical lianas belonging to the Ancistro-
cladaceae plant family. Representatives of these alka-
loids, such as ancistrocladinium A and B, exhibit
excellent antiinfective activities - for example, against
the pathogen Leishmania major - and thus serve as pro-
mising lead structures for the treatment of severe infec-
tious diseases [9-13]. This class of compounds
comprises complex natural products and newly devel-
oped synthetic analogues thereof [14-16] and provides a
rich repertoire of representatives with a large potential
against a number of infectious diseases, but potentially
also bears the risk of toxic effects in humans.
Starting from publicly available genome sequences
[17,18], genome annotation in the staphylococci strains
was completed by sequence and domain analysis [19] to
identify several previously unidentified metabolic
enzymes of their central metabolism. The respective
bioinformatic results obtained were validated by PCR
analysis. The obtained gene expression data helped to
monitor in detail the effect of different concentrations
of the isoquinoline on staphylococci. Also, the combina-
tion with metabolic modeling allowed us to fill in miss-
ing information on all central metabolic enzymes,
including those not affected by significant gene expres-
sion changes, and to obtain a complete view of the
resulting metabolic adaptations of the staphylococci.
These genome-scale predictions were further validated
by direct metabolite measurements on specific
nucleotides.
In general, the pathway modeling allows one to con-
sider network effects besides target effects (for instance,
on glycolysis, which decreases with increasing IQ-143
concentrations but is not a direct target of IQ-143) and
to find areas that are comparatively resistant (for exam-
ple, the pentose phosphate pathway). Gene expression
data are complemented by the network modeling and
from these counter regulation by higher gene expression
can be identified. Only a few metabolite measurements
are sufficient to validate the predictions regarding the
involved pathways - for example, here regarding nucleo-
tides as well as nucleotide-containing cofactors. We
tested the independence of the data sets carefully and
used them to also cross-validate the modeled pathway
fluxes - for example, whether the network predictions
from gene expression data fit measured nucleotide
concentrations.
Metabolic responses in human cells were modeled
considering measurements on cytochrome P450 (CYP)
detoxification data. We extrapolated again for all effects
on central pathways and compared the resulting predic-
tions to cytotoxicity data on human cells.
Results
IQ-143 added to a Staphylococcus epidermidis culture:
gene expression changes and metabolic model
IQ-143 has been identified by structure-activity relation-
ship studies in a screening program for compounds with
anti-staphylococcal activity [20]. To get a first hint of
the mode of action of this substance, DNA-microarray
experiments were conducted. The clinical S. epidermidis
strain RP62A was grown in the presence of IQ-143
(concentrations of a quarter of the minimum inhibitory
concentration and twice the minimum inhibitory con-
centration) as described in the Materials and methods
section and hybridized to full genome arrays. Significant
gene expression differences for S. epidermidis are shown
in Tables 1 and 2 (details shown in Additional file 1:
Table S5 lists gene expression differences for 1.25 μM
of IQ-143, Table S6 for 0.16 μM of IQ-143). Overall,
the expression of genes encoding proteins involved in
the transport of macromolecules, such as the ATP-bind-
ing cassette (ABC) transporter, the peptide transporter,
and the choline transporter, and metabolic enzymes of
carbohydrate pathways were especially significantly
affected.
To analyze pathway changes resulting from the mode
of action of IQ-143, including identification of affected
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Figure 1 Structure of IQ-143. Shown is the structure of the
environmental challenge and xenobiotic chosen, isoquinolinium salt
IQ-143, a structurally simplified analogue of a new subclass of
bioactive natural products, the N,C-coupled naphthyl-isoquinolines
alkaloids.
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enzymes that are not already apparent from the tran-
scriptome data, we applied YANAsquare [21,22] and a
custom-made routine written in R [23] for calculating
metabolic-flux changes after administration of IQ-143
(Figures 2 and 3).
The calculation of the pathway changes started from
the metabolic model of S. epidermidis (details in Table
S3 in Additional file 1) and applied the gene expression
data with significant expression changes (Table 1) as
flux constraints (Tables S10, S11 and S12 in Additional
file 1; detailed changes in Tables S16 and S17 in Addi-
tional file 1).
We first prepared a stoichiometric matrix in which the
rows and columns correspond to all the enzymes (for
annotation and collection see next chapter in results
and Materials and methods) in the network as well as
the internal metabolites of the network. The ‘internal’
metabolites inside the network have to be balanced:
Table 1 Gene expression changes measured after administration of IQ-143 in S. epidermidis RP62A
Gene expression after IQ-143 administration
Affected enzymes 0.00 μMa 0.16 μM 1.25 μM
OP_complex1 1.000 1.000 1.000
OP_complex2 1.000 1.000 1.000
OP_complex3 1.000 1.000 8.390
OP_complex4 1.000 1.000 1.000
OP_complex5a 1.000 1.000 1.000
SERP0290-zinc-transport_efflux 1.000 0.399 0.449
SERP0291-zinc-transporter_import 1.000 0.544 0.450
SERP0292-iron-dicitrate-transporter_import 1.000 0.544 0.430
SERP0389-EC:1.1.1.1-rn:R00754 1.000 1.000 3.070
SERP0653-EC:6.3.5.3-rn:R04463 1.000 1.000 0.491
SERP0655-EC:2.4.2.14-rn:R01072 1.000 1.000 0.436
SERP0656-EC:6.3.3.1-rn:R04208 1.000 1.000 0.424
SERP0657-EC:2.1.2.2-rn:R04325 1.000 1.000 0.426
SERP0658-EC:2.1.2.3-rn:R04560 1.000 1.000 0.439
SERP0659-EC:6.3.4.13-rn:R04144 1.000 1.000 0.392
SERP0686-spermidine/putrescine-transport_import 1.000 1.000 2.361
SERP0687-spermidine/putrescine-transport_import 1.000 1.000 2.208
SERP0688-spermidine/putrescine-transport_import 1.000 1.000 2.075
SERP0765-Uracil-permease-transport_import 1.000 1.000 2.765
SERP0831-EC:2.7.7.7-rn:R00375 1.000 1.000 2.202
SERP0831-EC:2.7.7.7-rn:R00376 1.000 1.000 2.202
SERP0831-EC:2.7.7.7-rn:R00378 1.000 1.000 2.202
SERP0831-EC:2.7.7.7-rn:R00379 1.000 1.000 2.202
SERP0841-EC:2.7.7.8-rn:R00437 1.000 1.000 2.867
SERP0841-EC:2.7.7.8-rn:R00439 1.000 1.000 2.867
SERP1403-MultiDrug-transport_efflux 1.000 1.000 2.063
SERP1802-cobalt/nickel-transport_efflux 1.000 1.000 2.401
SERP1803-cobalt/nickel-transport_efflux 1.000 1.000 2.301
SERP1944-MultiDrug-transport_efflux 1.000 1.000 2.075
SERP1951-lipoprotein-transport_efflux/import 1.000 1.000 0.457
SERP1952-macrolide-transport_efflux 1.000 1.000 0.386
SERP1997-formate/nitrite-transport_efflux/import 1.000 1.000 2.619
SERP2060-glyerol-transport_import 1.000 1.000 2.823
SERP2156-EC:1.1.1.27-rn:R00703 1.000 1.000 0.486
SERP2179-choline/betaine/carnitine-transp_efflux 1.000 7.071 2.389
SERP2186-EC:2.7.7.4-rn:R00529 1.000 1.000 0.349
SERP2283-phopsphonate-transport_import 1.000 1.000 2.680
SERP2289-MultiDrug-transport_efflux 1.000 1.000 1.971
This table shows the gene expression changes measured after administration of IQ-143. 1.0 denotes the standard activity without IQ-143. A value of 0.5 indicates
that the activity of this enzyme was halved after administration of IQ-143, a value of 2.075 indicates that the activity was doubled (again after administration of
IQ-143). aExpression with no IQ-143 (0.00 μM column) is set to 1.000 for normalization purposes.
Cecil et al. Genome Biology 2011, 12:R24
http://genomebiology.com/2011/12/3/R24
Page 3 of 18
tshould neither accumulate nor be lost over time. This
condition permits calculation of all enzyme combina-
tions that balance their metabolites inside the network.
This yields a list of all metabolic pathways possible for
this network [24]. In real situations, such as growth with
or without IQ-143, these possible pathways are used
quite differently. Next, we calculated the actual flux dis-
tribution with a specific program; to do this, direct
experimental data are required. The significantly
differentially expressed enzymes provide such data and
constraints on the flux distribution. This is, of course, a
simplification as enzyme activity is modulated allosteri-
cally and further factors are involved, such as stability of
mRNA and translational regulation. However, the com-
bined errors are strongly reduced by the high number of
constraints introduced by the gene expression data. For
the complete system of enzymes with significant gene
expression changes, the squared deviation between the
Table 2 Key effects of the measured gene expression differences after administration of IQ-143 compared to
untreated S. epidermidis RP62A
Concentration of IQ-143 (μM) Enzymes affecteda Effect on enzymesb Phenotypic effectsc
0.16 μM SERP0290-zinc-transport_efflux Down-regulated
SERP0291-zinc-transporter_import Down-regulated 40% biofilm inhibition
SERP0292-iron-dicitrate-transporter_import Down-regulated No growth inhibition
SERP2179-choline/betaine/carnitine-transp_efflux Up-regulated
1.25 μM SERP0290-zinc-transport_efflux Down-regulated
SERP0291-zinc-transporter_import Down-regulated
SERP0292-iron-dicitrate-transporter_import Down-regulated
SERP0653-FGAM synthetase-rn:R04463 Down regulated
SERP0655-amidophosphoribosyltransferase-rn:R01072 Down-regulated
SERP0656-AIR synthetase-rn:R04208 Down-regulated
SERP0657-GAR formyltransferase-rn:R04325 Down-regulated
SERP0658-AICAR transformylase-rn:R04560 Down-regulated ~100% biofilm inhibition
SERP0659-glycinamide ribonucleotide synthetase-rn:R04144 Down-regulated ~100% growth inhibition
SERP0686-spermidine/putrescine-transport_import Up-regulated
SERP0687-spermidine/putrescine-transport_import Up-regulated
SERP0688-spermidine/putrescine-transport_import Up-regulated
SERP0765-Uracil-permease-transport_import Up-regulated
SERP0831-DNA polymerase-rn:R00375 Up-regulated
SERP0831-DNA polymerase-rn:R00376 Up-regulated
SERP0831-DNA polymerase-rn:R00378 Up-regulated
SERP0831-DNA polymerase-rn:R00379 Up-regulated
SERP0841-PNPase-rn:R00437 Up-regulated
SERP0841-PNPase-rn:R00439 Up-regulated
SERP1403-MultiDrug-transport_efflux Up-regulated
SERP1802-cobalt/nickel-transport_efflux Up-regulated
SERP1803-cobalt/nickel-transport_efflux Up-regulated
SERP1944-MultiDrug-transport_efflux Up-regulated
SERP1951-lipoprotein-transport_efflux/import Down-regulated
SERP1952-macrolide-transport_efflux Down-regulated
SERP1997-formate/nitrite-transport_efflux/import Up-regulated
SERP2060-glyerol-transport_import Up-regulated
SERP2179-choline/betaine/carnitine-transp_efflux Up-regulated
SERP2186-ATP-sulfurylase;-rn:R00529 Down-regulated
SERP2283-phosphonate-transport_import Up-regulated
SERP2289-MultiDrug-transport_efflux Up-regulated
aLocus tags are given first (SERP numbers), followed by abbreviated biochemical name and then KEGG reaction numbers (always starting with - m:R...). The
effects on S. aureus USA300 were modeled (Table S20 in Additional file 1), are similar overall, and were validated by metabolite measurements. bDown-regulated
means that gene expression was halved (or more then halved); up-regulated means that gene expression was doubled (or more than doubled). Specific values
are given in Tables S5 and S6 in Additional file 1. All the enzymes with key changes in expression are part of the complete simulated metabolic model. cThe
phenotypes are combination effects of the complete networks, not of single modes (see also Figure S2 in Additional file 1).
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predicted enzyme activity according to the estimated
flux distribution and the observed enzyme activity was
minimized (least-square minimization combining the
genetic algorithm of YANAsquare with a custom written
R routine; see Materials and methods).
From the complete set of flux calculations, several
enzyme changes that were not detected by the transcrip-
tome data became apparent (Table 1). Certainly, these
are only predictions taking the network effects into
account. However, they were subsequently re-checked
using metabolite measurements (see below). Numerous
repetitions of the transcriptome measurements may also
have detected them, as more subtle differences then
become significant. On the other hand, the amount of
enzyme and activity is likely to be different from subtle
transcriptional changes. As an example, combined
effects on nucleotide and energy metabolism are
described in several extreme pathway modes (Table 1;
see, for example, modes 127 and 161 in Tables S7, S8,
S9, S10, S11, and S12 in Additional file 1). These flux
changes pertain to the enzymes (with EC numbers in
parentheses) PNPase (2.4.2.1), glucokinase (2.7.1.2),
deoxycytidine kinase (2.7.1.74), DNA-directed RNA
polymerase (2.7.7.6), deoxycytidine deaminase (3.5.4.14),
alpha-D-Glucose-1-epimerase (5.1.3.3), and glucose-6-
phosphate isomerase (5.3.1.9). Furthermore, changes in
amino acid metabolism became apparent from the flux
changes for modes 35 and 154. Enzymes involved in
energy and amino acid metabolism change their activity
after administration of IQ-143. This included citric
synthase (2.3.3.1), aconitate hydratase (4.2.1.3) and
acetyl-CoA synthetase (6.2.1.1) as well as enzymes
involved in the conversion of acetyl-CoA to L-valine
and the conversion of serine to cysteine.
Annotation of metabolic enzymes and flux balance
metabolic model for S. epidermidis and Staphylococcus
aureus
To establish an accurate model of the enzymes involved
in the response of staphylococci to IQ-143, we started
from the available genome sequences for S. epidermidis
[Genbank:CP000029, Genbank:CP000028] [17] and S.
aureus USA300 [Genbank:CP000730 and Genbank:
CP000255] [18] and applied biochemical data on staphy-
lococci according to the KEGG database [25]. We con-
sidered all pathways of primary metabolism: amino acid,
carbohydrate, lipid, and nucleotide synthesis and degrada-
tion, salvage pathways and energy metabolism (Figure 4).
ser_0.00μM ser_0.16μM ser_1.25μM
# Mode activity # Mode activity # Mode activity
[1-6] A: 1,00 N: 1,00 N: 0,70 N: 1,00 N: 1,00 N: 1,00 [1-6] A: 1,00 N: 1,00 N: 0,70 N: 1,00 N: 1,00 N: 1,00 [1-6] A: 1,00 N: 1,00 N: -0,67 N: 1,00 N: 1,00 N: 1,00
[7-12] N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 [7-12] N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 [7-12] N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00
[13-18] N: 1,00 N: 1,00 N: 1,00 E: 1,00 N: 0,91 N: 1,00 [13-18] N: 1,00 N: 1,00 N: 1,00 E: 1,00 N: 0,91 N: 1,00 [13-18] N: 1,00 N: 1,00 N: 1,00 E: 1,00 N: 1,00 N: 1,00
[19-24] N: 1,00 N: 1,00 A: 1,00 T: 1,00 N: 1,00 N: 1,00 [19-24] N: 1,00 N: 1,00 A: 1,00 T: 1,00 N: 1,00 N: 1,00 [19-24] N: 0,39 N 0,39 A: 1,00 T: 1,00 N: 1,00 N: 1,00
[25-30] N: -0,52 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: -1,33 [25-30] N: -0,52 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: -1,33 [25-30] N: -0,52 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: -1,33
[31-36] N: 1,00 A: 1,00 N: 1,00 E: 1,00 E: 0,91 E: -0,99 [31-36] N: 1,00 A: 1,00 N: 1,00 E: 1,00 E: 0,91 E: -0,99 [31-36] N: 1,00 A: 1,00 N: 1,00 E: 1,00 E: 1,00 E: 1,00
[37-42] N: 1,00 A: 1,00 N: 1,00 E: 0,50 AE: 0,50 N: 1,00 [37-42] N: 1,00 A: 1,00 N: 1,00 E: 0,50 AE: 0,50N: 1,00 [37-42] N: 1,00 A: 1,00 N: 1,00 E: 0,75 AE: 0,75 N: 1,00
[43-48] N: 1,00 N: 1,05 N: 0,73 E: 1,00 E: 1,00 E: 0,75 [43-48] N: 1,00 N: 1,05 N: 0,73 E: 1,00 E: 1,00 E: 0,75 [43-48] N: 1,00 N: 1,11 N: 0,67 E: 1,00 E: 1,00 E: 1,12
[49-54] E: 1,00 N: 1,00 N: 1,00 N: -1,34 N: 0,79 N: 0,53 [49-54] E: 1,00 N: 1,00 N: 1,00 N: -1,34 N: 0,79 N: 0,53 [49-54] E: 1,00 N: 1,00 N: 1,00 N: -1,74 N: 0,79 N: 0,53
[55-60] E: 0,53 N: 0,53 N: 0,53 N: 0,53 N: 0,92 N: 1,08 [55-60] E: 0,53 N: 0,53 N: 0,53 N: 0,53 N: 0,92 N: 1,08 [55-60] E: 0,53 N: 0,53 N: 0,53 N: 0,53 N: 0,92 N: 1,08
[61-66] N: -0,65 N: 0,92 EN: -0,48 N: 1,00 N: 1,00 N: 1,00 [61-66] N: -0,65 N: 0,92 EN: -0,48 N: 1,00 N: 1,00 N: 1,00 [61-66] N: -0,92 N: 0,92 EN: -0,45 N: 1,00 N: 1,00 N: 1,00
[67-72] N: 1,00 E: 1,00 EN: 1,00 N: 1,00 N: 1,00 N: 1,00 [67-72] N: 1,00 E: 1,00 EN: 1,00 N: 1,00 N: 1,00 N: 1,00 [67-72] N: 1,00 E: 1,00 EN: 1,00 N: 1,00 N: 1,00 N: 1,00
[73-78] N: 1,00 N: 1,00 N: 1,00 N: 1,00 T: 1,00 N: 1,00 [73-78] N: 1,00 N: 1,00 N: 1,00 N: 1,00 T: 1,00 N: 1,00 [73-78] N: 1,00 N: 2,62 N: 1,00 N: 1,00 T: 2,07 N: 1,00
[79-84] N: 0,55 A: 1,00 T: 1,00 N: 1,08 N: 1,00 T: 1,00 [79-84] N: 0,55 A: 1,00 T: 1,00 N: 1,08 N: 1,00 T: 1,00 [79-84] N: 0,28 A: 1,00 T: 1,00 N: 1,08 N: 1,00 T: 3,07
[85-90] E: 0,25 N: 1,00 A: 1,00 EN: 1,00 E: 1,00 N: 0,96 [85-90] E: 0,25 N: 1,00 A: 1,00 EN: 1,00 E: 1,00 N: 0,96 [85-90] E: 0,25 N: 1,00 A: 1,00 EN: 1,00 E: 1,00 N: 0,96
[91-96] N: 1,00 N: 0,67 N: 0,36 N: 0,41 N: 1,00 NT: 0,30 [91-96] N: 1,00 N: 0,67 N: 0,36 N: 0,41 N: 1,00 NT: 0,30 [91-96] N: 1,00 N: 0,67 N: 0,17 N: 1,09 N: 1,00 NT: 0,48
[97-102] EN: 0,35 N: 1,00 EN: 1,00 N: 0,36 N: 1,00 EN: 0,35 [97-102] EN: 0,35 N: 1,00 EN: 1,00 N: 0,36 N: 1,00 EN: 0,35 [97-102] EN: 0,69 N: 1,00 EN: 1,97 N: 0,01 N: 1,00 EN: 0,08
[103-108] EN: 1,00 N: 1,00 T: 1,00 NT: 1,00 A: 0,48 N: 1,00 [103-108] EN: 1,00 N: 1,00 T: 1,00 NT: 1,00 A: 0,48 N: 1,00 [103-108] EN: 2,30 N: 1,00 T: 1,00 NT: 1,00 A: 1,48 N: 1,00
[109-114] T: 0,92 N: 1,00 E: 1,00 N: 1,00 N: 1,00 A: 1,00 [109-114] T: 0,92 N: 1,00 E: 1,00 N: 1,00 N: 1,00 A: 1,00 [109-114] T: 0,92 N: 1,00 E: 1,00 N: 2,05 N: 1,00 A: 1,00
[115-120] N: 1,00 N: 0,19 N: 0,19 T: 1,00 A: 0,36 E: 0,36 [115-120] N: 1,00 N: 0,19 N: 0,19 T: 1,00 A: 0,36 E: 0,36 [115-120] N: 1,00 N: 0,00 N: 0,00 T: 1,00 A: 0,89 E: 0,36
[121-126] N: 0,25 T: 0,48 N: 1,00 T: 0,80 A: 1,00 N: 0,75 [121-126] N: 0,25 T: 0,48 N: 1,00 T: 0,80 A: 1,00 N: 0,75 [121-126] N: 0,25 T: 0,20 N: 1,00 T: 0,80 A: 1,00 N: 0,75
[127-132] N: 1,75 N: 1,00 A: 1,00 N: 1,40 N: 1,00 N: 1,00 [127-132] N: 1,75 N: 1,00 A: 1,00 N: 1,40 N: 1,00 N: 1,00 [127-132] N: 1,12 N: 1,00 A: 1,00 N: 1,40 N: 1,00 N: 1,00
[133-138] A: 1,00 T: 1,00 A: 1,00 N: 1,00 EN: 0,52 N: 1,00 [133-138] A: 1,00 T: 1,00 A: 1,00 N: 1,00 EN: 0,52N: 1,00 [133-138] A: 0,44 T: 1,00 A: 1,00 N: 1,00 EN: 0,83 N: 1,00
[139-144] N: 0,36 N: 0,19 N: 0,36 E: 1,00 N: 1,00 A: 1,00 [139-144] N: 0,36 N: 0,19 N: 0,36 E: 1,00 N: 1,00 A: 1,00 [139-144] N: 0,77 N: 0,00 N: 1,49 E: 1,00 N: 2,87 A: 1,00
[145-150] N: 1,00 A: 1,00 N: 1,00 NT: 0,64 T: 0,55 T: 0,91 [145-150] N: 1,00 A: 1,00 N: 1,00 NT: 0,64 T: 0,55 T: 0,91 [145-150] N: 2,20 A: 2,20 N: 2,20 NT: 0,00 T: 2,69 T: 0,00
[151-156] E: 0,56 N: 1,00 EN: 1,00 EO: 0,60 EO: 0,48 N: 1,00 [151-156] E: 0,56 N: 1,00 EN: 1,00 EO: 0,60 EO: 0,48N: 1,00 [151-156] E: 1,23 N: 1,00 EN: 1,00 EO: 0,43 EO: 0,17 N: 1,00
[157-162] EO: 1,00 E: 0,48 EO: 1,00 A: 1,00 AE: 0,66 N: 1,00 [157-162] EO: 1,00 E: 0,48 EO: 1,00 A: 1,00 AE: 0,66N: 1,00 [157-162] EO: 1,00 E: 1,60 EO: 1,00 A: 1,00 AE: 0,26 N: 1,00
[163-168] N: 1,00 N: 1,00 T: 1,00 EF: 0,25 N: 0,51 A: 0,25 [163-168] N: 1,00 N: 1,00 T: 1,00 EF: 0,25 N: 0,51 A: 0,25 [163-168] N: 1,00 N: 1,00 T: 1,00 EF: 0,25 N: 1,58 A: 0,25
[169-174] N: 1,00 N: 1,00 NT: 0,00 NT: 0,25 N: 0,48 N: 0,25 [169-174] N: 1,00 N: 1,00 NT: 0,00 NT: 0,25 N: 0,48 N: 0,25 [169-174] N: 1,00 N: 1,00 NT: 0,00 NT: 0,88 N: 0,48 N: 0,25
[175-180] A: 1,00 N: 1,00 EF: 1,00 EN: 1,00 N: 0,49 EN: 1,00 [175-180] A: 1,00 N: 1,00 EF: 1,00 EN: 1,00 N: 0,49 EN: 1,00 [175-180] A: 1,00 N: 1,00 EF: 1,00 EN: 1,00 N: 1,00 EN: 1,00
[181-186] EN: 1,00 N: 0,41 N: 0,48 N:1,00 N: 1,00 N: 1,00 [181-186] EN: 1,00 N: 0,41 N: 0,48 N:1,00 N: 1,00 N: 1,00 [181-186] EN: 1,00 N: 0,41 N: 0,48 N:1,00 N: 1,00 N: 1,00
[187-192] N: 1,00 A: 1,00 AE: 1,09 A: 1,00 N: 1,00 N: 1,00 [187-192] N: 1,00 A: 1,00 AE: 1,09 A: 1,00 N: 1,00 N: 1,00 [187-192] N: 1,00 A: 1,00 AE: 1,09 A: 1,00 N: 1,00 N: 2,68
[193-197] N: 1,00 N: 1,00 N: 0,56 T: 1,00 N: 1,00 [193-197] N: 1,00 N: 1,00 N: 0,56 T: 1,00 N: 1,00 [193-197] N: 1,00 N: 1,00 N: 0,56 T: 1,00 N: 0,49
Figure 2 Changes in extreme modes in S. epidermidis RP62A with three different concentrations of IQ-143. Red shading indicates lower
activities after IQ-143 administration, green shading indicates higher activities, and ‘ser’ denotes S. epidermidis. Each row displays the changes for
six extreme modes (continuously numbered from 1 to 197); numbers given in the fields are the activities for each mode under different
concentrations of IQ-143. Also given are the pathways in which the modes are involved. Abbreviations: A, amino acids; E, energy metabolism; F,
fatty acids; N, nucleotide metabolism; O, oxidative phosphorylation; T, transporters. All details are also shown in Additional file 1 (Tables S10, S11,
and S12; key changes in Tables S16 and S17).
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We established models for both S. aureus and S. epi-
dermidis; S. aureus is well known as a dangerous
pathogen, but infections by S. epidermidis (normally a
commensal of the skin) are increasingly common due
to the biofilm-forming capacity of this pathogen and
its development of resistance to a broad spectrum of
antibacterial agents [26].
We performed sequence and domain analyses [19] to
identify several enzymes that had escaped previous
annotation efforts, such as nucleoside-triphosphate
diphosphatase and thymidine phosphorylase in both
strains (Table S1 in Additional file 1), and verified their
occurrence in the cDNA of total RNA from S. epidermi-
dis by PCR (Figure 6S in Additional file 1). The genome
sequences were meticulously analyzed by sequence ana-
lysis. In addition, we searched in available data banks
for enzyme repertoires of both organisms, and different
enzyme reading frames were validated by PCR on the
mRNAs from these organisms. Any verified discrepan-
cies by these different checks were next incorporated
into the generated metabolic models so that pathways
with different enzyme repertoires are different in the
two models. For instance, S. aureus USA300 has only
one AMP-pyrophosphorylase and one GMP-pyropho-
sphorylase, whereas S. epidermidis RP62A has two of
each. On the other hand S. aureus USA300 has a XMP-
ligase, whereas S. epidermidis RP62A does not.
Our complete models (reactions in Tables S2 and S3
in Additional file 1) of metabolism in staphylococci sys-
tematically included all pathways for which gene expres-
sion data pointed to major changes (Tables 1 and 2) in
individual enzyme expression after applying different
concentrations of IQ-143. Furthermore, the metabolic
capabilities of these models were calculated applying
YANA [21].
Changes in reactions and enzyme activity of S. aureus
and S. epidermidis after administration of IQ-143
Using the above experimental data and the two strain-
specific metabolic models, we compared standard
growth to the reduced growth after administration of
IQ-143 (see Materials and methods). Several species-
specific differences with regards to reactions were
observed after administration of IQ-143 in S. aureus
compared to S. epidermidis. These are summarized in
Figures 2 and 3 (details in Tables S7, S8, S9, S10, S11
and S12). Thus, some modes are only up-regulated (for
example, modes 49 and 54 for pyrimidine metabolism in
S. aureus, but not in S. epidermidis) or only down-regu-
lated (for example, modes 44 and 193 for pyrimidine
sau_0.00μM sau_0.16μM sau_1.25μM
# Mode activity # Mode activity # Mode activity
[1-6] A: 1,00 N: 1,00 N: -0,65 N: 1,00 N: 1,00 N: 1,00 [1-6] A: 1,00 N: 1,00 N: -0,65 N: 1,00 N: 1,00 N: 1,00 [1-6] A: 1,00 N: 1,00 N: -0,66 N: 1,00 N: 1,00 N: 1,00
[7-12] N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 [7-12] N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 [7-12] N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00
[13-18] N: 1,00 N: 1,00 N: 1,00 N: 1,00 E: 0,96 N: 1,00 [13-18] N: 1,00 N: 1,00 N: 1,00 N: 1,00 E: 0,98 N: 1,00 [13-18] N: 1,00 N: 1,00 N: 1,00 N: 1,00 E: 0,97 N: 1,00
[19-24] N: 1,00 N: 1,00 N: 1,00 A: 1,00 T: 1,00 N: 1,00 [19-24] N: 1,00 N: 1,00 N: 1,00 A: 1,00 T: 1,00 N: 1,00 [19-24] N: 0,46 N: 1,00 N: 1,00 A: 1,00 T: 1,00 N: 1,00
[25-30] N: 0,45 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: -1,33 [25-30] N: -0,57 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: -1,33 [25-30] N: -0,59 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: -1,33
[31-36] N: 1,00 N: 1,00 A: 1,00 N: 1,00 E: 0,96 E: 1,00 [31-36] N: 1,00 N: 1,00 A: 1,00 N: 1,00 E: 0,96 E: 1,00 [31-36] N: 1,00 N: 1,00 A: 1,00 N: 1,00 E: 0,96 E: 1,00
[37-42] E: 1,00 N: 1,00 A: 1,00 N: 1,00 E: 1,00 AE: 1,00 [37-42] E: 1,00 N: 1,00 A: 1,00 N: 1,00 E: 1,00 AE: 1,00 [37-42] E: 1,00 N: 1,00 A: 1,00 N: 1,00 E: 1,00 AE: 1,00
[43-48] N: 1,00 N: 1,00 NE: 0,50 E: 1,00 N: 1,00 N: 1,00 [43-48] N: 1,00 N: 1,00 NE: 0,50 E: 1,00 N: 1,00 N: 1,00 [43-48] N: 1,00 N: 1,00 NE: 0,50 E: 1,00 N: 1,00 N: 1,00
[49-54] N: -0,87 N: -0,33 N: -0,33 N: -0,33 N: -0,33 N: -0,33 [49-54] N: -0,36 N: 0,40 N: 0,40 N: 0,40 N: 0,40 N: 0,40 [49-54] N: -0,36 N: 0,40 N: 0,40 N: 0,40 N: 0,40 N: 0,40
[55-60] N: 0,73 N: 0,72 N: 1,28 E: -0,50 N: 0,37 N:0,38 [55-60] N: 0,73 N: 0,72 N: 1,21 E: -0,50 N: 0,37 N:0,38 [55-60] N: 0,95 N: 0,92 N: 1,08 E: -0,50 N: -0,64 N:0,38
[61-66] E: 0,72 E: 0,51 N: 1,00 N: 1,00 N: 1,00 N: 1,00 [61-66] E: 0,88 E: 0,60 N: 1,00 N: 1,00 N: 1,00 N: 1,00 [61-66] E: 0,92 E: -0,48 N: 1,00 N: 1,00 N: 1,00 N: 1,00
[67-72] E: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 [67-72] E: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 [67-72] E: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00 N: 1,00
[73-78] N: 1,00 N: 1,00 N: 1,00 T: 1,00 N: 1,00 N 0,53 [73-78] N: 1,00 N: 1,00 N: 1,00 T: 1,00 N: 1,00 N 0,53 [73-78] N: 0,39 N: 1,00 N: 1,00 T: 2,30 N: 1,00 N 0,27
[79-84] A: 1,00 T: 1,00 N: 1,28 N: 1,00 T: 1,00 E: 0,25 [79-84] A: 1,00 T: 1,00 N: 1,12 N: 1,00 T: 0,54 E: 0,25 [79-84] A: 1,00 T: 1,00 N: 1,08 N: 1,00 T: 0,43 E: 0,22
[85-90] N: 1,00 A: 1,00 EN: 1,00 EN: 1,00 N: 1,00 N: 0,13 [85-90] N: 1,00 A: 1,00 EN: 1,00 EN: 1,00 N: 1,00 N: 1,03 [85-90] N: 1,00 A: 1,00 EN: 1,00 EN: 1,00 N: 1,00 N: 1,04
[91-96] N: 1,00 N. 0,67 N: 0,38 N: 0,16 N: 1,00 NT: 0,31 [91-96] N: 1,00 N. 0,67 N: 0,00 N: 0,23 N: 1,00 NT: 0,33 [91-96] N: 1,00 N. 0,67 N: 0,02 N: 0,39 N: 1,00 NT: 0,49
[97-102] N: 0,58 NT: 1,00 N: 1,00 N: 0,38 EN: 1,00 EN: 0,58 [97-102] N: 0,61 NT: 1,00 N: 1,00 N: 2,02 EN: 1,00 EN: 0,61 [97-102] N: 1,52 NT: 1,00 N: 2,68 N: 0,47 EN: 1,00 EN: 0,16
[103-108] N: 1,00 T: 1,00 NT: 1,00 A: 1,00 N: 0,49 T: 1,00 [103-108] N: 1,00 T: 1,00 NT: 1,00 A: 1,00 N: 0,40 T: 1,00 [103-108] N: 2,40 T: 1,00 NT: 1,00 A: 1,00 N: 1,41 T: 1,00
[109-114] N: 0,72 E: 1,00 N: 1,00 N: 1,00 A: 1,00 N: 1,00 [109-114] N: 0,88 E: 1,00 N: 1,00 N: 1,00 A: 1,00 N: 1,00 [109-114] N: 0,92 E: 1,00 N: 1,00 N: 2,87 A: 1,00 N: 1,00
[115-120] N: 1,00 N: 0,12 T: 0,12 N: 1,00 A: 0,38 EN: 0,38 [115-120] N: 1,00 N: 0,00 T: 2,02 N: 1,00 A: 0,00 EN: 2,02 [115-120] N: 1,00 N: 0,36 T: 0,83 N: 1,00 A: 0,54 EN: 1,01
[121-126] N: 0,25 T: 0,22 N: 1,00 T: 1,2000092 A: 1,00 N: 0,75 [121-126] N: 0,25 T: 1,00 N: 1,00 T: 0,80 A: 1,00 N: 0,75 [121-126] N: 0,25 T: 1,97 N: 1,00 T: 0,80 A: 1,00 N: 0,72
[127-132] N: 1,50 N: 1,00 A: 1,00 N: 0,60 N: 1,00 N: 1,00 [127-132] N: 1,50 N: 1,00 A: 1,00 N: 1,40 N: 1,00 N: 1,00 [127-132] N: 1,50 N: 1,00 A: 1,00 N: 1,40 N: 1,00 N: 1,00
[133-138] N: 1,00 A: 1,00 T: 1,00 A: 1,00 N: 0,55 EN: 1,00 [133-138] N: 0,47 A: 1,00 T: 1,00 A: 1,00 N: 0,57 EN: 1,00 [133-138] N: 0,45 A: 1,00 T: 1,00 A: 1,00 N: 0,85 EN: 1,00
[139-144] N: 0,38 N: 0,12 N: 0,38 N: 1,00 E: 1,00 N: 1,00 [139-144] N: 0,00 N: 0,00 N: 0,00 N: 1,00 E: 1,00 N: 1,00 [139-144] N: 0,59 N: 0,96 N: 1,14 N: 1,00 E: 2,20 N: 1,00
[145-150] A: 1,00 N: 1,00 N: 1,00 A: 0,60 N: 0,41 NT: 0,81 [145-150] A: 1,00 N: 1,00 N: 1,00 A: 0,57 N: 0,27 NT: 0,70 [145-150] A: 2,20 N: 2,20 N: 2,20 A: 2,66 N: 1,27 NT: 0,00
[151-156] T: 0,64 T: 1,00 E: 1,00 N: 0,57 EN: 0,45 EO: 1,00 [151-156] T: 0,72 T: 1,00 E: 1,00 N: 0,54 EN: 0,43 EO: 1,00 [151-156] T: 1,55 T: 1,00 E: 1,00 N: 0,00 EN: 0,15 EO: 1,00
[157-162] EO: 1,00 N: 0,22 EO: 1,00 E: 1,00 EO: 0,27 A: 1,00 [157-162] EO: 1,00 N: 1,00 EO: 1,00 E: 1,00 EO: 0,21 A: 1,00 [157-162] EO: 1,00 N: 2,06 EO: 1,00 E: 1,00 EO: 0,05 A: 1,00
[163-168] AE: 1,00 N: 1,00 N: 1,00 N: 0,25 T: 1,25 EF: 1,00 [163-168] AE: 1,00 N: 1,00 N: 1,00 N: 0,25 T: 1,25 EF: 1,00 [163-168] AE: 1,00 N: 1,00 N: 1,00 N: 0,25 T: 1,25 EF: 1,00
[169-174] N: 0,25 A: 1,00 N: 1,00 N: 1,00 N: 0,50 NT: 0,49 [169-174] N: 0,25 A: 1,00 N: 1,00 N: 1,00 N: 0,50 NT: 0,49 [169-174] N: 0,25 A: 1,00 N: 1,00 N: 1,00 N: 0,50 NT: 0,49
[175-180] NT: 0,25 N: 1,00 N: 1,00 A: 1,00 N: 1,00 EF: 0,75 [175-180] NT: 0,25 N: 1,00 N: 1,00 A: 1,00 N: 1,00 EF: 0,90 [175-180] NT: 0,25 N: 1,00 N: 1,00 A: 1,00 N: 1,00 EF: 0,80
[181-186] EN: 1,00 N: 1,00 NT: 0,15 N: 0,27 N: 1,00 N: 1,00 [181-186] EN: 1,00 N: 1,00 NT: 0,23 N: 0,21 N: 1,00 N: 1,00 [181-186] EN: 1,00 N: 1,00 NT: 0,53 N: 0,05 N: 1,00 N: 1,00
[187-192] N: 1,00 N: 1,00 A: 1,00 AE: 1,04 A: 1,00 N: 1,00 [187-192] N: 1,00 N: 1,00 A: 1,00 AE: 1,04 A: 1,00 N: 1,00 [187-192] N: 1,00 N: 1,00 A: 1,00 AE: 1,04 A: 1,00 N: 1,00
[193-198] N: 1,00 N: 1,00 N: 1,00 N: 1,08 T: 1,00 N: 1,00 [193-198] N: 1,00 N: 1,00 N: 1,00 N: 0,55 T: 1,00 N: 1,00 [193-198] N: 0,35 N: 1,00 N: 1,00 N: 0,52 T: 1,00 N: 2,82
Figure 3 Changes in extreme modes in S. aureus USA300 with three different concentrations of IQ-143. Red shading indicates lower
activities after IQ-143 administration, green shading indicates higher activities, and ‘sau’ denotes S. aureus. Each row displays six extreme modes
(continuously numbered from 1 to 198); numbers given in the fields are the activities for each mode under different concentrations of IQ-143.
Also given are the pathways in which the modes are involved. Abbreviations: A, amino acids; E, energy metabolism; F, fatty acids; N, nucleotide
metabolism; O, oxidative phosphorylation; T, transporters. All details are also shown in Additional file 1 (Tables S7, S8, and S9; key changes in
Tables S18 and S19).
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metabolism in S. epidermidis, but not changed in S. aur-
eus). Some metabolic modes are oppositely regulated in
the two strains. For example, mode 122 (involving sev-
eral transporter proteins for choline, carnithin and
betaine) is up-regulated in S. aureus but down-regulated
in S. epidermidis. Nevertheless, most of the calculated
metabolic fluxes were similar to those obtained for S.
epidermidis applying the gene expression data as con-
straints (Tables S18 and S19 in Additional file 1 detail
further changes). Several enzyme changes in S. epidermi-
dis and S. aureus that were not observable from the
transcriptome data became apparent only after applying
the metabolic modeling (Figures 5 and 6; bars with
dotted outlines indicate changes already indicated by the
gene expression data). For example, DNA-directed
RNA-polymerases do not change significantly in their
respective gene expression, but have clearly different
activities under the influence of different concentrations
of IQ-143.
The combination of all data with the strain-specific
metabolic models showed an effect of IQ-143 on energy
metabolism, DNA and RNA elongation as well as bac-
terial growth for both species (Figure S2 in Additional
file 1).
The activity increase in extreme pathway mode 61
(Table S18 in Additional file 1) for the enzymes glu-
cose-6-phosphate isomerase (5.3.1.9), alpha/beta D-glu-
cokinase (2.7.1.1), adenylate kinase (2.7.4.10), and D-
glucose-1-epimerase (5.1.3.3) is only visible in S. aureus.
Pathway effects of different concentrations of IQ-143 in S.
epidermidis and S. aureus
Metabolic modeling took advantage of enzyme gene
expression changes from the array data by using these
data as constraints for the metabolic flux calculations.
This allowed us to estimate the effects of different
degrees of environmental change after the administra-
tion of different concentrations of IQ-143 on not only
Primary metabolism
TCA cycle
&
oxidative phosphorylation
&
pentose phosphate pathway
Glycolysis
Amino acid metabolism:
all 20 amino acids
Fatty acid metabolism:
beta oxidation, lipid synthesis
Purine metabolism
Pyrimidine metabolism
Intermediary 
metabolism
Redox 
protection
Salvage pathway
Secondary metabolism
Figure 4 Simplified view of the metabolic chart for S. aureus and S. epidermidis, focusing on central metabolic pathways of interest.
This flow chart illustrates which pathways of the primary metabolism are incorporated into our models. Note that the secondary metabolism is
not a part of our model. TCA, tricarboxylic acid.
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the metabolism of individual enzymes but also on entire
pathways. Using the gene expression changes as con-
straints in a metabolite flux model to estimate the
changes in individual metabolic fluxes after administra-
tion of IQ-143, YANAsquare allowed us to calculate the
resulting change for each flux and all enzymes in the
network [22]. The constraints on the gene expression of
several enzymes are of course only a simple first-order
estimate of enzyme activity. However, it turned out that
the given number (31) of constraints in the model,
which were estimated according to significant gene
expression changes as well as the tight connections
between different pathways in the metabolic network,
are sufficient for optimized flux estimates. In particular,
the estimated fluxes are in accordance with the mea-
sured experimental metabolite concentrations and their
changes (see below).
One could expect a general stress response from the
administered IQ-143. In fact, we identified stress
response mechanisms of S. epidermidis RP62A against
IQ-143 (Table 3). However, we found significant up-reg-
ulation of stress response genes only for two genes after
looking at all genes that were up-regulated: SERP2244
and SERP1998. SERP2244 encodes a bacterial capsule
synthesis protein (PGA_cap), which may help the bac-
teria to resist high salt concentrations and may also be
involved in virulence [27,28]. SERP1998 is a putative
activator of the Hsp90 ATPase homolog 1-like protein.
Up-regulation of Hsp90 results in higher survival under
conditions of increased stress [29,30]. However, genes
belonging to the sigmaB-dependent stress regulon are
not affected by IQ-143. Furthermore, the transcriptome
data show that several ABC transporters are up-regu-
lated by IQ-143. ABC transporters are often involved in
multi-drug resistance as they function as trans-mem-
brane efflux pumps for active transport of several xeno-
biotics, including anti-infective substances [31]. In
staphylococci, several ABC transporters, such as MsrA
(conferring resistance to macrolides, lincosamides, strep-
togramins), TetK (conferring resistance to tetracycline),
NorA (conferring resistance to fluoroquinolones),
VgaAB (conferring resistance to streptogramins), and
FusB (conferring resistance to fusidic acid), have been
shown to be involved in antibiotic resistance [32].
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Figure 5 Effects of IQ-143 on metabolic enzymes of S. aureus. Detailed data are given in Table 4. The insert shows the different enzyme
color codes. Many differences are apparent after applying metabolic modeling; bars with dotted outlines and brackets around the enzyme name
highlight those enzymes in which the different gene expression values already indicate a significant change after administration of IQ-143.
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However, the ABC transporters deregulated by IQ-143
in this study have not been documented to be involved
in resistance to xenobiotics yet. Further studies are
needed to clarify the exact role of these transporters in
resistance.
Gene expression differences (Table 1) and detailed
modeling of metabolism suggest that key changes are
not located in just one particular subnetwork: DNA and
RNA elongation is up-regulated (two-fold), and oxida-
tive phosphorylation complex 3 is up-regulated (eight-
fold). By contrast, glycolysis as well as lactate dehydro-
genase (1.1.1.27) are down-regulated (by 50%).
In particular, enzymes of the oxidative phosphoryla-
tion and purine pathways are primarily affected upon
application of IQ-143 (Table 4). In purine metabolism,
the enzymes utilizing inosine monophosphate (IMP) are
impeded as well as complex 1 and 3 (Figures 5 and 6)
of oxidative phosphorylation. Also, there is a drop in
activity of some DNA and RNA polymerases. Figures 2
and 3 provide detailed information on the complete
metabolic effects calculated from the data using
YANAsquare [22].
The changes in complexes 1 and 3 are of particular
interest. These significant changes in activity suggest
Table 3 Identification of stress response mechanisms in S. epidermidis RP62A11
Hit
Query Family Description Entry type Clan Bit score E-value
SERP2244 PGA_cap Bacterial capsule synthesis protein PGA_cap Domain CL0163 233.2 2.3e-69
SERP1998 AHSA1 Activator of Hsp90 ATPase homolog 1-like protein Family CL0209 67.8 6.9e-19
This table provides BLAST [48] results of the two putative stress response mechanisms of S. epidermidis RP62A we detected by iterative sequence search.
PGA_cap encodes a poly-gamma-glutamate capsule, which could improve the survivability under salt stress. AHSA1 encodes an activator of the Hsp90 ATPase
homolog 1-like protein, which results in an increase of efficiency of the Hsp90 function and thus leads to higher survivability under stress conditions.
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Figure 6 Effects of IQ-143 on metabolic enzymes of S. epidermidis. Detailed data are given in Table 4. The insert shows the different
enzyme color codes. Many differences are apparent after applying metabolic modeling; bars with dotted outlines and brackets around the
enzyme name highlight those enzymes in which the different gene expression values already indicate a significant change after administration
of IQ-143.
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two possible modes of action for IQ-143: either NADH
is not produced in a sufficient quantity any more due to
various effects of IQ-143, or the compound competes in
a direct way with NADH in certain enzymes. Regarding
the first possibility, IMP-utilizing enzymes are also
affected by IQ-143 if administered at a concentration of
at least 1.25 μM (Tables S20 and S21 in Additional file
1). In particular, S. epidermidis and S. aureus have to
use enzymes located in the glycolysis and pentose phos-
phate pathway to produce enough ribosylamine-5-phos-
phate, the initial step in IMP production. Some of these
reactions use NAD+ and produce NADH as a co-sub-
strate (for example, glyceraldehyde-3-phosphate dehy-
drogenase in lower glycolysis). NAD+-utilizing enzymes
Table 4 Effects of IQ-143 on diverse enzymes of oxidative phosphorylation and energy and nucleotide metabolism of
S. aureus USA300 and S. epidermidis RP62A
Concentration of IQ-143 (μM)b
Enzymea 0.00 0.16 1.25
S. aureus USA300
OP_complex1 0.0396 0.0260 0.0310
OP_complex2 0.0396 0.0260 0.0310
[OP_complex3] 0.0791 0.0520 0.0619
OP_complex4 0.0396 0.0260 0.0310
OP_complex5 0.0214 0.0109 0.0031
PurM_DNA-directed-RNA-polymerase_ATP 0.0791 0.0000 0.0000
PurM_DNA-directed-RNA-polymerase_CTP 0.0396 0.0260 0.0310
PurM_DNA-directed-RNA-polymerase_GTP 0.0396 0.0260 0.0310
PurM_DNA-directed-RNA-polymerase_UTP 0.0285 0.0229 0.0285
[SERP0831-PurM_DNA-directed-DNA-polymerase_dATP] 0.0396 0.0260 0.0121
[SERP0831-PurM_DNA-directed-DNA-polymerase_dCTP] 0.0396 0.0260 0.0310
[SERP0831-PurM_DNA-directed-DNA-polymerase_dGTP] 0.0396 0.0260 0.0310
[SERP0831-PurM_DNA-directed-DNA-polymerase_dTTP] 0.0396 0.0260 0.0310
[SERP0841-PurM_PNPase_ADP] 0.0791 0.0520 0.0619
[SERP0841-PurM_PNPase_GDP] 0.0265 0.0174 0.0207
Glyc_glyceraldehyde-3-P-dehydrogenase_NAD+ 0.1582 0.1040 0.1238
Glyc_glyceraldehyde-3-P-dehydrogenase_NADP+ 0.0601 0.2102 0.1251
TCA_pyruvate_dehydrogenase 0.0396 0.0260 0.0310
S. epidermidis RP62A
OP_complex1 0.0201 0.0201 0.0126
OP_complex2 0.0161 0.0161 0.0050
[OP_complex3] 0.0361 0.0361 0.0175
OP_complex4 0.0334 0.0334 0.0292
OP_complex5 0.0669 0.0669 0.0585
PurM_DNA-directed-RNA-polymerase_CTP 0.0334 0.0334 0.0292
PurM_DNA-directed-RNA-polymerase_GTP 0.0120 0.0120 0.0436
PurM_DNA-directed-RNA-polymerase_UTP 0.0334 0.0334 0.0292
PurM_DNA-directed-RNA-polymerase_ATP 0.0334 0.0334 0.0292
[SERP0831-PurM_DNA-directed-DNA-polymerase_dATP] 0.0334 0.0334 0.0766
[SERP0831-PurM_DNA-directed-DNA-polymerase_dCTP] 0.0224 0.0224 0.0196
[SERP0831-PurM_DNA-directed-DNA-polymerase_dGTP] 0.0334 0.0334 0.0292
[SERP0831-PurM_DNA-directed-DNA-polymerase_dTTP] 0.0468 0.0468 0.0409
[SERP0841-PurM_PNPase_ADP] 0.0669 0.0669 0.0585
[SERP0841-PurM_PNPase_GDP] 0.0120 0.0120 0.0050
Glyc_glyceraldehyde-3-P-dehydrogenase_NAD+ 0.0669 0.0669 0.0585
Glyc_glyceraldehyde-3-P-dehydrogenase_NADP+ 0.0241 0.0241 0.0228
TCA_pyruvate_dehydrogenase 0.0161 0.0161 0.0468
This table lists the effects of three different concentrations of IQ-143 on the activity of diverse enzymes of the described pathways and reactions in S. aureus
USA300 and S. epidermidis RP62A. aEnzymes in brackets were also detected by their gene expression change in S. epidermidis RP62A. bConcentrations tested were
no IQ-143, 0.16 μM IQ-143 and 1.25 μM IQ-143. PurM, purine metabolism.
Cecil et al. Genome Biology 2011, 12:R24
http://genomebiology.com/2011/12/3/R24
Page 10 of 18
are significantly down-regulated by 10 to 15% (see
Tables S20 and S21 in Additional file 1). One scenario
of drug action for IQ-143 predicts that if IMP synthesis
is impaired (at least 1.25 μM IQ-143), there is less
NADH available. This, in turn, is responsible for the
drop in efficiency of complex 1 of oxidative phosphory-
lation, which thus also impedes complex 3. This theory
is supported by the results shown in Table 5 for higher
concentrations of IQ-143, where the changes in nucleo-
tide concentrations after application of IQ-143 to S. aur-
eus are shown. Whereas 0.16 μM IQ-143 reduced AMP
concentration by approximately 70% (control, 0.42 μg/
ml; 0.16 μM IQ-143, 0.12 μg/ml), an almost 50-fold
increase in AMP concentration was observed with 1.25
μM IQ-143 (Table 6). Such an accumulation of AMP is
most likely the consequence of decreased production of
ATP by oxidative phosphorylation.
A second potential mode of action for IQ-143 would
be that it directly acts as a NADH competitor and
impairs the production of NAD+. This again leads to the
effects described above, although this time the reduced
pool of NAD+ and not the inhibition of NADH-produ-
cing enzymes is responsible for the calculated effects.
Metabolite measurements in S. aureus
To better examine these possibilities, we conducted
direct metabolite measurements by HPLC-UV and
quantitatively measured the metabolic changes due to
the administered xenobiotic IQ-143 (that is, metabo-
nomics as defined by Nicholson [33]). In contrast to the
modeled metabolic fluxes (see the previous section of
Results), these are direct measurements and are used to
validate and re-test the predictions regarding the result-
ing metabolite levels.
The data show a complex pattern of cell alterations
upon administration of IQ-143: the nicotinamide-ade-
nine dinucleotides NAD+, NADH and NADP show sub-
stantial decreases of between 10 and 30% and between
30 and 50% dependent on the applied concentration of
the inhibitor (0.16 μM and1.25 μM IQ-143, respectively;
Figure 7). In turn, the reduced phosphate form NADPH
undergoes a two-fold increase (with 1.25 μM IQ-143).
Table 6 gives an overview of the metabolite measure-
ments and shows significant differences in these with
various concentrations of applied IQ-143.
Additionally, strong changes occurred in the metabolite
profile of purine metabolism. Pathway modeling of these
data suggests down-regulation of purine metabolism as
well as further effects also on the pyrimidine metabolism.
Thymidine-5’-monophosphate (TMP) and cytidine-5’-
monophosphate (CMP) show statistically significant
changes: the concentration of TMP increased five-fold
upon treatment with 1.25 μM IQ-143, and CMP produc-
tion was reduced to 20% compared to the control. The
lower inhibitor concentration (0.16 μM) resulted in only
a slight increase in CMP. The concentrations of all
nucleotides increase at high concentrations of IQ-143
(Figure 8, Table 5). By contrast, the changes with low IQ-
143 concentrations are more heterogeneous.
Metabolic effects of different concentrations of IQ-143 on
human cells
The combined effects of IQ-143 are bacteriostatic and,
at higher concentrations, bactericidal on S. aureus and
Table 5 Concentrations of CMP, AMP, GMP, XMP, and TMP
Control 0.16 μM IQ-143 1.25 μM IQ-143
Mean (μg/ml) SD Mean (μg/ml) SD % of control Mean (μg/ml) SD % of control
CMP 21.03 0.96 24.41* 0.24 116.07 3.86** 0.19 18.35
TMP 1.61 0.12 1.67 0.11 103.76 8.81* 0.24 547.20
AMP 0.42 0.06 0.12* 0.02 28.57 20.37** 0.80 4850.00
GMP 1.51 0.05 1.44** 0.05 95.36 3.66* 0.21 242.38
XMP 2.62 0.20 3.96** 0.16 151.15 3.44** 0.11 131.30
Direct measurement of CMP, AMP, GMP, XMP, and TMP concentrations in S. aureus (in μg/ml and in percentage of control value depending on the applied IQ-
143 concentration). Statistically significant differences are indicated (*P < 0.05,**P < 0.01). SD, standard deviation.
Table 6 Concentration of NAD, NADH, NADP, and NADPH
Control 0.16 μM IQ-143 1.25 μM IQ-143
Mean (μg/ml) SD Mean (μg/ml) SD % of control Mean (μg/ml) SD % of control
NAD 42.19 2.44 35.68** 0.92 84.57 27.89** 0.95 66.11
NADH 3.71 0.31 2.63** 0.28 70.89 1.95** 0.21 52.56
NADP 3.47 0.06 3.24** 0.05 93.37 2.42** 0.05 69.74
NADPH 2.87 0.12 2.25** 0.02 78.40 5.56** 0.22 193.73
Direct measurement of NAD, NADH, NADP, and NADPH concentrations in S. aureus (in μg/ml and percentage of control value depending on the applied IQ-143
concentration). Statistically significant differences are indicated (*P < 0.05,**P < 0.01). SD, standard deviation.
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S. epidermidis. This supports the use of IQ-143 as a
potential antibiotic lead compound for the development
of a novel class of antibiotics against staphylococcal
infections. However, for clinical application, the thera-
peutic width and toxic effects in human cells have to be
considered. As a start in this direction, we combined
direct measurements in cultured human cells with in
vitro measurements of enzyme activity of the CYP oxi-
dase system involved in xenobiotic detoxification (Table
7). The direct measurements in cultured human cells
revealed IC50 values that indicate that IQ-143 has toxic
effects (see Materials and methods) on human kidney
293T human embryonal cells and macrophage (J774.1)
cells at a dose of approximately 40 μM.
With regard to the in vitro measurements, we experi-
mentally investigated the effects of IQ-143 on the six
main human liver drug metabolizing CYP enzymes,
1A2, 2C8/9/19, 2D6 and 3A4, using a previously
developed and well-established in vitro test system
[15,34,35]. Only at high concentrations of IQ-143 (100
μM) was inhibition apparent: CYP 3A4 is strongly inhib-
ited (Table 7; Figure S3 in Additional file 1); and two
other enzymes are partially inhibited, CYP2C19 only
slightly (5% loss of activity) and CYP2D6 moderately
(40% loss of activity).
Human cells and staphylococcal cells show only few
differences in their core enzyme composition of primary
metabolism. For the human cell model the enzymes
were compared in both organisms according to the
KEGG database, extended by our own sequence analysis
(Tables S1 and S4 in Additional file 1). After taking
minor differences into account, we assumed as a worst-
case scenario that the effects (and metabolic or gene
expression changes) of IQ-143 administration in staphy-
locci are comparable to those in human cells. We thus
applied similar constraints (gene expression changes for
key enzymes) to the modified metabolic model for the
human cells. To the human model we also added the
detoxification pathways of the six human CYP enzymes.
Applying the constraints apparent for no, low (1 μM or
10 μM), or high concentrations of IQ-143 (100 μM) -
three CYP enzymes partially or fully inhibited - we
tested next whether this is predicted to affect other
pathway fluxes in the human cell model (for calculations
see Materials and methods). With the exception of the
partial block of the cytochrome isoenzymes at high con-
centrations of IQ-143, there was no other block pre-
dicted for any of the other pathways modeled. In
accordance with the experimental observations, this
would imply low toxicity of IQ-143 in cell culture.
Discussion
Modeling adaptation processes
There is an urgent need to find new antibiotics against
staphylococci due to the emergence and alarming spread
of resistant strains not only in hospitals but, more
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Figure 7 Measured changes of nucleotides upon addition of
0.16 μM and 1.25 μM IQ-143. The results represent mean values
of triplicate measurements (± standard deviation). For further details
see Tables 5 and 6.
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Figure 8 Measured changes of energy metabolism upon
addition of 0.16 μM and 1.25 μM IQ-143. The results represent
mean values of triplicate measurements (± standard deviation). For
further details see Tables 5 and 6.
Table 7 Effects on human cytochrome P450 function in
vitro
Cytochrome enzyme Percentage of control activity
1 μM IQ-143 10 μM IQ-143 100 μM IQ-143
1A2 106.9 127.3 126.2
2C8 142.8 144.0 146.0
2C9 122.7 130.0 142.0
2C19 102.2 101.8 90.1
2D6 99.1 100.9 58.7
3A4 98.6 95.3 6.6
CYP enzymes derived from baculovirus-infected insect cells were incubated
with the corresponding substrates and IQ-143 at concentrations of 1 μM, 10
μM, and 100 μM as described by Unger and Frank [34]. As shown here (and in
Figure S3), only very high doses of IQ-143 reduced the activity of the CYP
isoenzymes 2C19, 2D6, and 3A4. At concentrations below 100 μM IQ-143, the
activities were even higher compared to those of the control group.
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recently, also in the community. In particular, drugs
belonging to novel chemical classes are of broad interest
as it is assumed that resistance development against
such substances will be minimized. In addition, the
identification of novel targets may accelerate the finding
of new lead substances combating multi-drug-resistant
pathogens [36]. The compound IQ-143 has no cytotoxic
effects at low concentrations in human cells compared
to other isoquinoline compounds. In this study, we have
included systems-wide approaches coupled with bioin-
formatic modeling and host-detoxification enzyme
effects to elucidate the mode of action of the antimicro-
bial compound IQ-143 in different staphylococci; it
shows direct application of systems biology in antibiotic
research [37].
Our combination of theoretical modeling, analysis of
enzyme activity, measurement of metabolite concentra-
tions as well as the incorporation of gene expression
data allowed us to describe in large-scale models the
diverse effects of the antibiotic compound IQ-143 on
the metabolism of both pathogens (S. aureus and S. epi-
dermidis) and human host cells. These approaches are
complementary to each other: direct toxicity data were
only partially available and metabolite measurements
covered only a range of nucleotides, including NAD(P)
(H). Our work demonstrates how metabolic modeling
can help to fill in missing information and how this
allows predictions on the enzyme activities of the com-
plete network, which subsequently can be verified by
the experimental measurements. As a requirement for
the modeling, the genome sequences were partly re-
annotated.
Such a combined approach is of general use in meta-
bonomics [33] to model, for instance, the effects of var-
ious different isoquinolines and other drugs, the effects
of genetic mutations, or even more complex interactions
between hosts and pathogens (for example, the metabo-
lism of S. aureus under persistence in the host).
Our results suggest that IQ-143 targets the energy
metabolism of S. epidermidis and S. aureus (Table 4)
and we observed severely limited growth of S. epidermi-
dis and S. aureus when IQ-143 was applied. On the
other hand (as shown by array data here), gene expres-
sion for DNA and RNA polymerases was not down-
regulated by IQ-143, but was instead up-regulated (up
to two-fold). Our modeling can explain both findings.
IQ-143 does not affect the DNA and RNA polymerase
chain as initially suspected (Table 2), but rather inter-
feres with the energy metabolism.
An example is mode 102, which consists of a pyru-
vate-phosphotransferase and a PEP-carboxylase. The
activity of this particular mode is reduced by one-half
after administration of IQ-143 in both staphylococci
strains. In general, the metabolism of sugars and
alcohols is reduced by IQ-143 and the investigated
pathogens counteract this effect by expressing more
DNA and RNA polymerases (and other enzymes) in
order to maintain appropriate turnover in these
pathways.
The general stress response is not strongly activated in
S. epidermidis after administration of IQ-143 (only two
genes are turned on). Several ABC transporter genes,
which probably encode multiple drug efflux pumps, are
turned on in the presence of IQ-143. These are typical
responses of S. epidermidis against toxic agents [38].
However, for IQ-143 the specific pathway effects are
more important and stronger.
Metabolic implications
By analyzing CYP enzyme activity, this study enables the
inhibitory potential of IQ-143 towards the major human
drug metabolizing CYP enzymes to be assessed. In con-
trast to several previously tested naphthylisoquinoline
alkaloids [15], which showed extraordinarily strong and
selective inhibition of CYP2D6, IQ-143 did not show a
remarkable inhibition of CYP2D6 or other tested isoen-
zymes at the relevant concentrations of 1 and 10 μM.
Owing to the low inhibitory activity of the compound,
the possibility of drug-drug interactions is very small.
Even for CYP3A4, the major human CYP isoenzyme in
the gut and liver, inhibition is unlikely because its activ-
ity is significantly reduced only at a concentration of
100 μM, which will not be achieved in the human body.
This also reveals that certain structural characteristics
might be avoided when developing new drugs from IQ-
143 in order to minimize toxic effects occurring through
protein inhibition.
The two investigated Staphylococcus species use NAD
(H) as an energy source for oxidative phosphorylation.
In accordance with this, the results of metabolite mea-
surements show lower concentrations of NAD+ and
NADH. However, NADPH levels increased at the high-
est concentrations of IQ-143. Therefore, we believe that
NADPH-producing enzymes (for example, of the pen-
tose-phosphate pathway) and NADH-producing
enzymes (including glyceraldehyde-3P-dehydrogenase,
which can use both NADH as well as NADPH) are
probably not the primary targets of the inhibition.
Instead, IQ-143 has to directly affect NADH consump-
tion. By inhibiting complex 1 of oxidative phosphoryla-
tion, NADH consumption is severely affected even at
low concentrations of IQ-143; NADH is consumed at a
significantly reduced rate, which leads to a smaller
quantity of available NAD+. Glyceraldehyde-3P-dehydro-
genase, however, is not affected by this, and nor are the
NADPH-using enzymes. As modeling shows, this leads
to much higher production of NADPH since less and
less NAD+ is available.
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Our theory is supported by experimental findings (see
‘Results: Pathway effects of different concentrations of
IQ-143 in S. epidermidis and S. aureus’ as well as Tables
5 and 6) and data from the literature. Aromatic sub-
stances with a quaternary nitrogen, such as the quinoli-
nium-derived drug dequalinium chloride, tend to
accumulate in mitochondria [39,40]. Also, the interfer-
ence of the mitochondrial respiratory chain, especially
complex I, by quaternary isoquinoline derivatives such
as N-methylisoquinolinium ions or N-methyl-1,2,3,4-tet-
rahydroisoquinoline is well known [41,42]. Since IQ-143
is structurally related to dequalinium chloride, interac-
tion of this newly identified antimicrobial compound
with the mitochondrial respiratory chain is possible.
Additionally, our findings are supported by the results
in Table 5, which lists the changes in nucleotide con-
centrations after application of IQ-143 to S. aureus.
Whereas 0.16 μM IQ-143 reduced the AMP concentra-
tion by approximately 70% (control, 0.42 μg/ml;
0.16 μM IQ-143, 0.12 μg/ml), an almost 50-fold
increase in AMP concentration was observed using a
concentration of 1.25 μM IQ-143 (Table 5). Increased
AMP concentration due to a breakdown of the labile
ATP molecule can be excluded because the control
incubation was processed in the same way as the sam-
ples treated with IQ-143. Presumably, the accumula-
tion of AMP points to direct inhibition of NADH
oxidation by complex I of the respiratory chain
because blocking electron transport leads directly to
the breakdown of the chemoosmotic potential and,
subsequently, oxidative phosphorylation.
The effects of secondary metabolites of the compound,
host-pathogen interactions and more complex system
effects have not been investigated in this work. How-
ever, since the first mouse experiments suggested that
IQ-143 is toxic, this substance should currently only be
considered as a lead structure for future drug develop-
ment based on the promising results regarding antibiosis
in staphylococci and to negate toxic effects in the host.
Certainly this theoretical suggestion requires further
experimental tests.
Conclusions
Utilizing our model, the apparent bacteriostatic and, at
higher concentrations, bactericidal effects of IQ-143 in
S. aureus and S. epidermidis can now be described in
detail according to its effects on the activity of specific
enzymes and pathways in these organisms, in particular
on energy metabolism and DNA/RNA elongation. IQ-
143 administration affects oxidative phosphorylation but
also has an impact on purine metabolism, including
direct effects on purine metabolism and other nucleo-
tide-producing enzymes at higher concentrations as well
as pathway effects observable, for example, in glycolysis.
These effects can be explained by the drug interfering
with the NAD(H) pool and the multi-enzyme complexes
of oxidative phosphorylation. The network effects can
only be seen through modeling since measurements of
metabolites are able to show only a small part of the
whole metabolome. The metabolic effects are also not
observable in the gene expression data either unless
they lead to significant changes in gene expression. By
applying data gathered from the metabolite measure-
ments, the models can be fitted and thus made more
accurate than when based on gene expression data
alone.
This permits improvement of the lead substance (for
example, pro-drug or testing of further modifications).
Our combination of modeling and experimental data is
generally suited to elucidate organism-wide metabolic
adaptations to xenobiotics in a comparative way. Future
extensions will include further data sets, such as addi-
tional data on toxicity and enzyme kinetics.
Materials and methods
Microarray analysis
Total RNA was isolated from S. epidermidis strain
RP62A grown in the presence of 0.16 μM (one-quarter
of the minimal inhibitory concentration) and 1.25 μM
(twice the minimal inhibitory concentration) IQ-143 and
without the drug. For the analysis of gene expression
with subinhibitory concentrations of IQ-143, an over-
night culture of S. epidermidis RP62A was diluted to an
optical density OD600nm of 0.05 in a 50 ml flask. To this
culture 0.16 μM IQ-143 was added and the culture was
grown with agitation (200 rpm) until OD600nm reached
1.0. To analyzing the impact of inhibitory concentra-
tions of IQ-143, 1.25 μM of the substance was added to
the cultures in the exponential growth phase (OD600nm
of 1.0) and the cultures were grown for an additional 10
minutes. Bacteria were harvested with the addition of
RNA Protect (QIAGEN, Hilden, Germany) according to
the manufacturer’s instructions. Prior to RNA isolation,
bacteria were lysed using glass beads in a Fast Prep sha-
ker (Qbiogene, Heidelberg, Germany) for 45 s at a speed
of 6.5 units. RNA was isolated using a QIAGEN RNeasy
kit according to the standard QIAGEN RNeasy protocol.
S. epidermidis RP62A full genome microarrays con-
taining PCR products of 2,282 genes/open reading
frames were used for microarray analysis (Scienion, Ber-
lin, Germany). DNA expression data have been depos-
ited in the public databank repository Protecs [43,44]
(accession [PROTECS:IQ-143]).
Total RNA (10 μg) for DNA microarray analysis iso-
lated from cultures in the exponential growth phase was
used for reverse transcription and fluorescent labeling
reactions using random primers and Superscript III
reverse transcriptase (Invitrogen, Darmstadt, Germany).
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cDNA was concomitantly labeled using the dyes Cy3
and Cy5 according to the manufacturer’s instructions
(Scienion, Dortmund, Germany). RNA obtained from
twelve (0.16 μM) and six (1.25 μM) different biological
experiments was utilized, and a reverse labeling (dye
switch) experiment was performed to minimize bias due
to differential dye bleaching or incorporation of the Cy3
and Cy5 dyes during the reverse transcription reaction.
Microarray hybridization (16 h at 50°C) and washing of
the slides were performed according to the manufac-
turer’s instructions. Hybridized slides were scanned
using a Genepix 4000B laser scanner (Axon Instruments
Inc., Union City, CA, USA). Bioinformatic analyses on
the slide hybridization results of each single experiment
were performed using Genepix Pro3.0 (Axon Instru-
ments Inc.). Data for each image were normalized to the
mean ratio of means of all features.
Reconstruction of metabolic networks
To model involved metabolic pathways, we used the
KEGG database [24]. Additional genome annotation of
missing enzyme activities for the central pathways was
determined using iterative sequence and domain analysis
methods [19]. Subsequent experimental verification by
PCR complemented this (Tables S1, S2, S3, and S4, and
Figure S6 in Additional file 1). The model of central
metabolism included lipid, amino acid, and central car-
bohydrate metabolism as well as nucleotide and salvage
pathways.
Metabolic flux modeling
Extreme pathways possible in the annotated enzyme
network were calculated first [24]. To identify actual
flux strengths, we used YANAsquare [21,22] and a cus-
tom written program in R [23]. We modeled flux
strengths in the metabolic webs of S. aureus USA300
and S. epidermidis RP62A according to gene expression
data obtained for the purpose (Tables S5 and S6 in
Additional file 1). A least square fit used first YANAs-
quare and next the improved R routine to calculate
optimal pathway fluxes that best matched the con-
straints for key enzyme activities as estimated according
to significant elevated or lowered enzyme expression in
the above data sets (Table 1; Tables S5 and S6 in Addi-
tional file 1). Additional metabolite measurements (Fig-
ures 7 and 8) probed whether the metabolite
concentrations were correctly predicted. Measured CYP
activity data were considered next in the model to test
whether inhibition of CYP enzymes affected other path-
ways in their fluxes.
Detailed input files for the pathway models are pro-
vided in Additional file 1 (for S. aureus USA300 in
Table S2; for S. epidermidis RP62A inTable S3). The
calculated activities of the different extreme pathway
modes for no IQ-143 and two different concentrations
of it are listed in Tables S7, S8, and S9 (S. aureus), S10,
S11, and S12 (S. epidermidis), and S12, S13, S14, and
S15 (human).
Cell culture
Cells of S. aureus USA300 and S. epidermidis RP62A
were cultured in Luria-Bertani-Medium at 30°C and
shaken at 170 rpm. After 2 hours, IQ-143 was added:
0.8 μl of a 20 mM stock solution of IQ-143 in dimethyl
sulfoxide was added per 100 ml cell culture to attain a
concentration of 0.16 μM. For a concentration of 1.25
μM, 6.25 μl per 100 ml cell culture were added. The
cells were harvested when an OD of 1.0 was reached
and the metabolites were extracted. Toxicity assays in
human cells were conducted according to [15]. Concen-
trations tested included 0.16 μM and 1.25 μM IQ-143,
and a control with no antibiotic added.
In vitro inhibitory activity of IQ-143 on CYP enzymes
To test the inhibitory activity of IQ-143 on the six main
human drug-metabolizing CYP enzymes, we applied the
method described by Unger and Frank [34]. The
enzymes CYP1A2, 2C8/2C9/2C19, 2D6 and 3A4 were
derived from baculovirus-infected insect cells and were
incubated with different concentrations of IQ-143 (1,
10, and 100 μM).
IC50 determination for human cells
J774.1 macrophages were cultured in complete medium
(RPMI with NaHCO3, 10% fetal calf serum, 2 mM gluta-
mine, 10 mM Hepes pH 7.2, 100 U/ml penicillin, 50 μg/
ml gentamicin, 50 μM 2-mercaptoethanol) without phe-
nol red in the absence or presence of increasing concen-
trations of the compounds at a cell density of 1 × 105
cells/ml (200 μl) for 24 h at 37°C, 5% CO2 and 95%
humidity. Following the addition of 20 μl of Alamar
Blue, the plates were incubated and the ODs measured
at 24 h, 48 h, and 72 h. The standard Alamar blue assay
was performed as previously described [45].
Kidney epithelial 293T cells (2 × 104 cells/ml) were
tested in the same manner as the macrophages except
that complete DMEM medium was used: 4.5 g/l solu-
tion of DMEM high D-glucose solution with sodium
pyruvate but without L-glutamine, fetal bovine serum
superior at a final concentration of 20%, 200 mM L-glu-
tamine 100x.
Commercial sources of standards for the metabolite
measurements
The standards were obtained from the following suppliers.
AppliChem (Darmstadt, Germany): b-nicotinamide ade-
nine dinucleotide (NAD), b-nicotinamide adenine dinu-
cleotide phosphate sodium salt (NADP), b-nicotinamide
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adenine dinucleotide reduced dipotassium salt (NADH),
and b-nicotinamide adenine dinucleotide 2’-phosphate
reduced tetrasodium salt (NADPH). Sigma (Taufkirchen,
Germany): adenosine 5’-monophosphate sodium salt,
cytidine 5’-monophosphate disodium salt, dextromethor-
phan, imipramine, inosine 5’-monophosphate disodium
salt, guanosine 5’-monophosphate disodium salt hydrate,
midazolam, paclitaxel, reserpine, tacrine, tolbutamide,
thymidine 5’-monophosphate disodium salt hydrate,
xanthosine 5’-monophosphate disodium salt, and sodium
chloride. Fluka (Buchs, Switzerland): tributylamine and
formic acid (purissimum grade). Fisher Scientific
(Schwerte, Germany): methanol and acetonitrile. Natutec
(Frankfurt, Germany): recombinant CYP1A2, CYP2C8,
CYP2C9, CYP2C19, CYP2D6 and CYP3A4 from baculo-
virus-infected insect cells co-expressed with P450 reduc-
tase and cytochrome b5.
Cell culture harvesting and HPLC
Cultivated cells (S. aureus and S. epidermidis) were
quenched by adding methanol 50% (v/v). After washing
the cell pellet with 0.9% sodium chloride it was
extracted with methanol 80% (v/v) by means of ultraso-
nic treatment. After centrifugation the supernatants
were directly analyzed by HPLC using an Agilent Sys-
tem 1100 LC (Waldbronn, Germany) consisting of a
vacuum degasser, a binary pump, an autosampler, a
thermostatted column compartment and an UV-visible
diode array detector. System control and data processing
were performed using the Agilent ChemStation Software
revision A.10.01.
Determination of purine and pyrimidine nucleotides
(CMP, AMP, IMP, GMP, TMP and XMP)
The HPLC methods for the analysis of the purine and
pyrimidine nucleotides were adapted from Schmitz et al.
[46]. A sample volume of 10 μl was injected onto a 150
× 4.6 mm internal diameter, 4 μm Synergi Fusion RP
column (Phenomenex, Aschaffenburg, Germany). The
mobile phase consisted of water (A) and acetonitrile (B),
both containing 5 mM tributylamine and 0.1% formic
acid. The following gradient (percentage B) was applied:
0 to 5 minutes, 5%; 15 minutes, 20%; 18 minutes, 20%.
After 18 minutes the column was flushed with 100% B
for 3 minutes and re-equilibrated with 5% B. The flow
rate was set to 1 ml/minute and the temperature for the
column was set to 25°C. As all nucleotides show high
UV absorption at about 260 nm, this wavelength was
chosen for detection. All measurements were performed
in triplicate. The external calibration for quantification
was carried out through measurement of a mixture of
the corresponding nucleotides covering a range between
0.5 and 100 μg/ml.
Determination of nicotinamide derivatives (NAD, NADH,
NADP, NADPH)
For the HPLC analysis of the nicotinamide derivatives the
same method as described for the nucleotides was
applied. However, the gradient (percentage B) was
slightly varied: 0 to 5 minutes, 5%; 15 minutes, 50%; 18
minutes, 50%. After 18 minutes the column was flushed
with 100% B for 3 minutes and re-equilibrated with 5% B.
Statistical analysis
Statistical analysis was performed using the Mann-Whit-
ney U-test by means of the software Statistica 8.0 (Stat-
Soft (Europe) GmbH, 20253 Hamburg, Germany); P-
values were calculated in relation to corresponding con-
trols (pooled values).
Additional data and scripts
As well as Additional file 1, other files are available from
[47], containing: an introduction to pathway modeling in
general and a tutorial for working with YANAsquare;
input files for YANAsquare needed to calculate the
extreme modes; scripts for R for calculation of the
effects of changing gene expression after administration
of IQ-143 (these are also used for a statistical evaluation
of said effects); and scripts for PERL to import the
results from R to YANAsquare.
Additional material
Additional file 1: Supplementary materials. Additional file 1 is a Word
document containing additional data on sequence comparisons,
pathway models, synthesis and effects of the IQ-143 compound, gene
expression data, and nucleotide and NAD measurements, as reported in
the manuscript.
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